
Alzheimer’s Medication Shows Promise for Treatment of Disease in Phase III Trials
Alzheimer’s disease is the sixth leading cause of death in the U.S., but researchers have recently completed the first phase III clinical trial for a drug that targets a specific protein linked to the progression of the disease. The protein in question is called tau, and is responsible for forming twisted fibers in the brain…